Ketamine: Benefits and Risks for Depression, PTSD & Neuroplasticity

Episode 136 Aug 7, 2023 Episode Page ↗
Overview

Andrew Huberman, a Stanford Professor, explains ketamine's clinical uses for depression, PTSD, and suicidality, detailing its brain mechanisms (NMDA, BDNF, opioid pathways) and neuroplasticity. He also covers recreational risks, dosages, and administration routes.

At a Glance
13 Insights
1h 39m Duration
16 Topics
9 Concepts

Deep Dive Analysis

Ketamine: Clinical Uses, Recreational Abuse, and Mechanisms

Ketamine's Similarity to PCP and Historical Perceptions

History of Depression Treatment: Monoamine Hypothesis Limitations

Preclinical Models of Depression: Learned Helplessness

Ketamine's Clinical Applications: Depression, Suicidality, PTSD

Ketamine Treatment Durability and Mechanisms of Action

NMDA Receptor Function and Neuroplasticity

Excitatory vs. Inhibitory Neurons and Ketamine's Paradoxical Plasticity

Acute vs. Long-Term Effects of Ketamine on Brain Function

Brain-Derived Neurotrophic Factor (BDNF) and Ketamine's Role

Ketamine's Impact on the Opioid Pathway

Divergent Mechanisms of Immediate and Long-Term Effects

Habenula, Reward Pathway, and Antidepressive Behaviors

The Nature of Ketamine-Induced Dissociative States

Ketamine Dosages, Administration Routes, and Risks

Ketamine Forms (R, S, SR) and Microdosing Efficacy

Monoamine Hypothesis of Depression

This hypothesis suggests that depression is caused by deficiencies in monoamine neurotransmitters like serotonin, dopamine, or norepinephrine. While drugs increasing these can help some, there's little evidence for actual monoamine deficiencies in depression, and these treatments only work for about 40% of depressed individuals.

Learned Helplessness Model

A preclinical model of depression where an animal (rat or mouse) is placed in water and its duration of swimming before giving up is measured. This behavior helps researchers quantify the antidepressant effects of various compounds.

NMDA Receptor

A receptor on neuron surfaces that acts as an 'AND gate,' requiring both high or unusual electrical activity and glutamate binding to activate. Its activation is crucial for many forms of neuroplasticity, enabling neurons to change and adapt to new activity patterns.

Excitatory Neurotransmission

A type of neural communication where one neuron releases neurotransmitters, primarily glutamate, that increase the likelihood of the next neuron becoming electrically active, essentially stimulating it.

Inhibitory Neurotransmission

A type of neural communication where neurons release neurotransmitters, mainly GABA, that reduce the likelihood of the next neuron becoming electrically active, thereby suppressing its activity.

Ketamine's Paradoxical Neuroplasticity

Ketamine blocks NMDA receptors, which are vital for neuroplasticity. However, it selectively blocks NMDA receptors on *inhibitory* neurons, reducing their suppression of *excitatory* neurons. This leads to increased, bursting activity in excitatory neurons, which paradoxically *induces* neuroplasticity in mood-related circuits.

Brain-Derived Neurotrophic Factor (BDNF)

A crucial molecule that acts as a growth factor in the brain, binding to TRAC-B receptors. It triggers cascades that insert new glutamate receptors and can alter neuron shape, making circuits highly plastic. Ketamine appears to induce BDNF release and may even mimic its effects.

Dissociative State

A state induced by ketamine, typically at sub-anesthetic doses, where individuals feel detached from their body, observing themselves from a third-person perspective. This is linked to an uncoupling of neocortical and subcortical networks and a shift in brain wave patterns from alpha to theta.

Habenula

A brain structure involved in disappointment and pro-depressive behaviors, which normally provides inhibitory input to the brain's reward pathway. Ketamine therapy can lessen this inhibition, making the reward pathway more accessible for engagement through daily life activities.

?
What is ketamine and how is it used?

Ketamine is a fascinating compound used clinically to treat depression, suicidality, and PTSD, but it also has a high potential for recreational abuse. It is classified as a dissociative anesthetic, similar to PCP.

?
Can ketamine be addictive?

Yes, people can get addicted to ketamine; some individuals find themselves compelled to use it even when its use negatively impacts their overall life performance, including work, school, relationships, and finances.

?
How quickly does ketamine relieve depression, and how long do the effects last?

Ketamine can provide relief from depression within minutes to hours of administration, with the immediate effects lasting about two hours. The antidepressant effects can persist for several days (at least three days) to a week after a single treatment, but often wear off without a repeated regimen.

?
How does ketamine cause neuroplasticity despite being an NMDA receptor blocker?

Ketamine blocks NMDA receptors primarily on inhibitory neurons, which reduces their suppressive effect on excitatory neurons. This leads to increased, bursting activity in excitatory neurons, which then *induces* neuroplasticity in mood-related brain circuits.

?
What is a 'K-hole' in scientific terms?

A 'K-hole' describes the subjective experience when someone takes a dose of ketamine that pushes them beyond a dissociative state into a pseudo-anesthetized state, transitioning towards full anesthesia, often associated with recreational use.

?
Are there different forms of ketamine, and which is most effective for depression?

Yes, ketamine exists in R, S, and combined SR forms. Clinical trials suggest the combined SR form is the most potent and effective for relieving depressive symptoms, followed by the S form, with the R form being the least potent.

?
Is microdosing ketamine effective for depression?

As of current published scientific and clinical literature, there is zero evidence that microdosing ketamine is effective for treating depression. All positive effects on depression have been observed with higher, sub-anesthetic doses.

?
How does ketamine affect the brain's reward system?

Ketamine treatment can reduce the inhibitory output from the habenula (a disappointment circuit) to the brain's mesolimbic reward pathway, making the reward pathway more available for engagement. It also strengthens connections between the frontal cortex (context-dependent strategy) and these reward pathways.

?
Does the subjective experience of ketamine therapy directly cause long-term depression relief?

It is not clear that the immediate subjective experience of ketamine (e.g., euphoria, dissociation) is solely responsible for long-term depression relief. Studies suggest that the antidepressant effects may also involve the opioid system and neuroplastic changes that occur over days and weeks.

1. Integrate Antidepressive Behaviors

For lasting mental health benefits from drug treatments, actively engage in ‘antidepressive behaviors’ such as morning sunlight, quality sleep, proper nutrition, and social engagement to reinforce positive neural changes.

2. Prioritize Foundational Mental Health

Support mental health by consistently viewing morning sunlight, ensuring regular and sufficient quality sleep, maintaining proper nutrition, and engaging in proper social interactions.

3. Reinforce Neural Changes Actively

To maximize benefits from treatments, actively seek stimulating work, social engagement, and comprehensive self-care, as neural circuits respond to these specific patterns of thinking and behavior.

4. Avoid Nighttime Blue Light

Refrain from viewing blue light between 11 p.m. and 4 a.m. to prevent activation of a pro-depressive circuit that lowers dopamine and increases cortisol.

5. Hydrate with Electrolytes Daily

Dissolve one packet of Element in 16-32 ounces of water and drink it first thing in the morning, and also during any physical exercise, to maintain optimal hydration and electrolyte balance.

6. Restore Energy with NSDR

Utilize yoga nidra or Non-Sleep Deep Rest (NSDR) protocols for short 10-minute sessions to significantly restore levels of cognitive and physical energy.

7. Use Ketamine Clinically

If considering ketamine for treatment, ensure its use is strictly within an appropriate clinical context, adhering to prescribed dosages and frequency, due to its high potential for abuse and associated risks.

8. Caution: Ketamine Outside Clinic

Understand that taking prescribed ketamine outside of a clinical setting carries significant risks, including potential for recreational abuse and addiction.

9. Avoid Ketamine K-hole Doses

Do not take ketamine at doses that induce a ‘K-hole’ (full-blown anesthesia), as this state can be dangerous and potentially deadly, particularly when combined with other drugs such as barbiturates or alcohol.

10. Ketamine & Seizure Risk

Individuals who are seizure-prone, whether due to epilepsy, prior head injury, or unknown predisposition, should avoid ketamine due to its potential to induce seizures by disrupting brain inhibition.

11. Avoid Driving on Ketamine

As ketamine is a sedative, exercise extreme caution and avoid activities such as driving or walking in traffic while under its influence.

12. No Ketamine Microdosing for Depression

Avoid microdosing ketamine for the treatment of depression, as current scientific and clinical literature provides no evidence of its effectiveness at such doses.

13. Understand Ketamine’s Dual Effects

Recognize that ketamine produces both immediate subjective effects like dissociation and euphoria, as well as long-term changes in neural circuitry, regardless of clinical or recreational use.

The acute or immediate effects of ketamine, while one is under the influence of ketamine, are just part of the story of how ketamine modifies the brain for the treatment of depression, suicidality, and PTSD.

Andrew Huberman

The monoamine hypothesis of depression is really centered around the idea that it is deficiencies in these monoamines, either serotonin or dopamine or norepinephrine or some combination of those that gives rise to depression. Now, in reality, there is very little, if any, evidence that there is a deficiency of monoamines in any form of depression.

Andrew Huberman

If you are somebody suffering from depression, even another day, even another hour with depression seems almost unmanageable. And sadly, many people who have these forms of depression will go on to commit suicide. So it is ever so important that there be rapid treatments for depression, even same day treatments for depression. And based on this study, it appeared that ketamine was, and indeed still remains, that drug.

Andrew Huberman

Brain function is a series of accelerators and brakes. It's not all about neurons stimulating other neurons. It's also about neurons preventing the activation of other neurons. That's just central to everything, not just preventing seizures, but it's central to learning. It's central to vision. It's central to hearing. It's central to creativity. It is at the core of brain function.

Andrew Huberman

Better living through chemistry still requires better living.

Andrew Huberman

Ketamine Therapy for Depression (Durable Effects)

Andrew Huberman
  1. Administer ketamine (e.g., 0.5 mg/kg intravenously, or equivalent via other routes) twice per week.
  2. Continue this regimen for a total duration of three weeks.
  3. After the three-week period, individuals may experience ongoing relief from depressive symptoms for months or more before needing to repeat the treatment schedule.
40%
Percentage of depressed people responding to monoamine-increasing drugs Many people also experience significant side effects.
Within 10-15 minutes
Time for antidepressant effects of intravenous ketamine to take place Immediate relief observed in clinical studies.
45 minutes to 1 hour
Time for peak euphoric state after intravenous ketamine injection Part of the acute effects.
Approximately 2 hours
Duration of total euphoric effects after intravenous ketamine injection Refers to the acute subjective experience.
At least 3 days to 1 week
Duration of antidepressant effects from a single ketamine treatment Effects often wear off if treatment is not repeated.
0.5 milligrams per kilogram (mg/kg)
Typical intravenous/intramuscular dosage for depression treatment Induces dissociative states without full anesthesia.
1 to 2 milligrams per kilogram (mg/kg)
Ketamine dosage range for anesthetic effects Can lead to full loss of consciousness.
25%
Percentage of active ketamine reaching bloodstream when taken orally Requires higher oral doses to achieve effects comparable to injection.
Approximately 35%
Percentage of active ketamine reaching bloodstream when taken sublingually Requires higher sublingual doses to achieve effects comparable to injection.